US 12,357,657 B2
Silver-/gold-compounds and methods thereof
Hongzhe Sun, Hong Kong (HK); Pak Leung Ho, Hong Kong (HK); Runming Wang, Hong Kong (HK); Hongyan Li, Hong Kong (HK); and Qi Zhang, Hong Kong (HK)
Assigned to THE UNIVERSITY OF HONG KONG, Hong Kong (HK)
Appl. No. 17/632,242
Filed by THE UNIVERSITY OF HONG KONG, Hong Kong (HK)
PCT Filed Aug. 21, 2020, PCT No. PCT/CN2020/110444
§ 371(c)(1), (2) Date Feb. 2, 2022,
PCT Pub. No. WO2021/036923, PCT Pub. Date Mar. 4, 2021.
Claims priority of provisional application 62/890,667, filed on Aug. 23, 2019.
Prior Publication US 2022/0296639 A1, Sep. 22, 2022
Int. Cl. A61K 33/242 (2019.01); A61K 31/28 (2006.01); A61K 31/555 (2006.01); A61K 31/66 (2006.01); A61K 31/7135 (2006.01); A61K 38/12 (2006.01); A61P 31/04 (2006.01)
CPC A61K 33/242 (2019.01) [A61K 31/28 (2013.01); A61K 31/555 (2013.01); A61K 31/66 (2013.01); A61K 31/7135 (2013.01); A61K 38/12 (2013.01); A61P 31/04 (2018.01)] 9 Claims
 
1. A pharmaceutical composition, comprising:
at least one polymyxin antibiotic comprising at least one of colistin A or colistin B; and
at least one mobile colistin resistant proteins inhibitor comprising a silver compound,
wherein a molar ratio of the at least one polymyxin antibiotic to the at least one mobile colistin resistant proteins inhibitor is from 16:1 to 64:1 by weight (w/w).